Journal of Liver

Journal of Liver
Open Access

ISSN: 2167-0889


Lian-yu Chen

Lian-yu Chen


  • Case Report
    Complete Response of Hepatocellular Carcinoma to Sorafenib: A Case Report and Review of Literatures
    Author(s): Lian-yu Chen, Kun Wang and Zhen ChenLian-yu Chen, Kun Wang and Zhen Chen

    Background: Sorafenib is the current standard treatment for advanced and unresectable hepatocellular carcinoma (HCC). Although the efficacy of sorafenib on the overall survival and time to progression has been repeatedly proven, clinically evident and sustainable response especially Complete Response (CR) is rarely observed after its treatment. Case Report: We report a case of a 64-year old female patient with unresectable HCC who received sorafenib treatment of more than 8 months following a Transarterial Chemoembolization (TACE) treatment. The patient had a rapid and complete response within 1 month of sorafenib treatment, which sustained for more than 7 months after the initiation of the therapy. Conclusions: This result suggests that sorafenib alone or its use with TACE may be useful in the treatment of unresec.. Read More»
    DOI: 10.4172/2167-0889.1000164

    Abstract PDF

Relevant Topics